chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Originally I only had a tender injection site for 3-4 days. Just to preface, I?m a flight attendant and was on a trip  (left 1/29). I?ve tried to keep all the times in EST. On 1/30, my feet and hands started to itch intensely around 3 PM. I thought it was due to the detergent on the hotel sheets. 1/31 I took one Benadryl around 4AM. It took the itch away. Around noon the itching returned so I used Eurlax cream which didn?t do much, by the time I arrived home Around 430 PM, my hips and back were covered with a rash but only my hips itched lightly. I took another Benadryl. I decided to go to a testing site to see if they knew if it was related to the vaccination. While at the site I got a rapid and PCR test. On the flight, my smell disappeared but I ( thought) I could still taste. It began to return on 1/31. No other symptoms. My rapid test came back positive for COVID on 1/31 6PM. I have not received my PCR (blizzard and faculties closed ).  Over the past few days, the rash has mainly been on my upper legs, torso, and head/face. It itches to the point I have scratch marks. My Dr put me on prednisone and anti itching cream. I don?t notice a difference. The Benadryl helps bit makes me sleepy. I?m going to try cetirizine tomorrow. I will also be getting allergy tested for PEG when the Dr will allow me to visit.
Information has been received from a healthcare worker referring to a 19 year old male patient. Information about concurrent conditions, medical history and concomitant medication was not provided. On 27-MAY-2015 the patient was vaccinated with a pediatric dose of VAQTA (lot # K018181, dose, dose# and route not provided). No adverse experience has been reported. The outcome of the event was not provided. Additional information has been requested.
Sometime in late june/early july, I noticed a bald spot on the back of my head. It enlarged and new ones were forming. I saw the dermatologist on Aug 4 and was prescribed Clobetasol and given monthly Cortizone injections in Sept and Oct. After bad reactions, after a month of use as directed, I stopped use. I tried to continue use in two later periods, then stopped.   I was given a Rheumatologist referal and saw this Dr. in Oct. The test results were negative. I have follow-up in Dec.  I'm diagnosed with acute Alopecia Areata. Shortly after my 3rd cortizone injection appt. (early Oct) I accepted the use of headcoverings and ceased with the injections.    use of headcoverings and decided to cease injections.  After initial info gathering about Alopecia Areata I found a book on the subject. After the negative test results with the Rheumatologist, I looked at the chapters in the book. The book mentions reasearchers suspecting viruses "could trigger an imballance of immune responses" The book also rejects the longstanding belief that the condition can be caused by stress. I'm mentioning this because the Derm. Provider said this was most likley the cause.  This bit of information, the time of onset and the grey hairs make me suspect that the condition may have been caused by the Vaccine. I was trying to be informed about the condition and look for other info in a book. I'm not diagnosing myself. This info caused suspicion. I think the scruffy grey hairs within the bald spots and surrounding some spots could be a medical sign. I looked at internet image results of alopecia areata. I did'nt see any with the greying. I think this supports my belief about something unusual.
Anaphylactic reaction to vaccine; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of ANAPHYLACTIC REACTION (Anaphylactic reaction to vaccine) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 050C21A and 016C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for Antihistamine therapy, MULTIVITAMINS [VITAMINS NOS] for Vitamin supplementation.   On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Jun-2021, the patient experienced ANAPHYLACTIC REACTION (Anaphylactic reaction to vaccine) (seriousness criterion medically significant). The patient was treated with ALBUTEROL [SALBUTAMOL] on 02-Jun-2021 for Anaphylaxis, at an unspecified dose and frequency. On 02-Jun-2021, ANAPHYLACTIC REACTION (Anaphylactic reaction to vaccine) had resolved.            On 02 Jun 2021, after the vaccination patient began to experience shortness of breath at 12:30 pm and patient's airways started to constrict at around 9:00 pm. Therefore patient went to the hospital.  Action taken with mRNA-1273 in response to the events was not applicable. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. Further information has been requested.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. Further information has been requested.
7 doses mixed with non-supplied diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Hib (Hiberix) (batch number BA975, expiry date 16th May 2023) for prophylaxis.   On an unknown date, the patient received Hiberix. On an unknown date, unknown after receiving Hiberix, the patient experienced wrong solution used in drug reconstitution. On an unknown date, the outcome of the wrong solution used in drug reconstitution was unknown.   Additional Information: GSK Receipt Date: 20-SEP-2022 Reporter's Comment: The medical assistant reported staff discovered that 7 doses of Hiberix were potentially mixed with non-supplied diluent when they were reconstituted for administration.  It was believed the doses were reconstituted with sterile water diluent from Merck that was used for reconstituting proquad vaccines. The reporter did not had patient details at the time of reporting.  The reporter did not know dates of administration. The reporter consent to follow up. Additional supportive information: Hiberix reconstituted with sterile water instead of the GlaxoSmithKline supplied diluent, which led to wrong solution used in drug reconstitution. This case is 1 of 7 cases reported by same reporter.; Sender's Comments:  US-GSK-US2022AMR136360:Same reporter. US-GSK-US2022AMR136361:Same reporter. US-GSK-US2022AMR136348:Same reporter. US-GSK-US2022AMR136362:Same reporter. US-GSK-US2022AMR136364:Same reporter. US-GSK-US2022AMR136365:Same reporter
Second dose of vaccine was given on 3-13-21, patient started having symptoms of cough and fainting spell on 10-27-21, patient was admitted through ED for one day on 10-27-21, discharged on 10-28-21, unsure if any labs were done or if any imaging was done. Unknown if patient has recovered fully.
Aches and fatigue for 24 hours after shot. Delayed period two months out. First period after dosing was 4 days late. Second period after dosing was 2 days late.
Blood clots in lungs. Had trouble breathing for 3 days before it was diagnosed in the er.
I have  Dermatomyositis and CK was low in  2020. After taking the shot, of course I had a fever or other symtoms in the lists  ( like malaise etc )  But, my right leg muscle started hurting , so went to see a doctor . CK was about 380.  The pain didn't go away but I took the 2nd shot.  After the that, CK became 449.  My left shoulder and arm  muscles hurt a lot and  found CK was already went up to 1,464. Right now taking steroid and Immunosuppressant. I hadn't have Dermatomyositis symtoms for over 10 years but suddenly showed up,  I think this means it's related to the vaccine.
Chest pain started 11/20/21, 2 days after receiving the vaccine. Patient did not seek medical treatment until the Wednesday after, 11/24/2021. Patient was instructed by his primary care physician to go to nearest emergency room.
vasovagal reaction while walking from vaccination station to observation. Transported to EMS room for observation. Pt reports that this happens when he gets blood draws. No complaints, given H2O and allowed to rest discharged in stable condition.
Diagnosed with a condition that made him immunocompromised; This spontaneous case was reported by a pharmacist and describes the occurrence of IMMUNODEFICIENCY (Diagnosed with a condition that made him immunocompromised) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033h21a, 024m20a and 042l20a) for COVID-19 prophylaxis.     No Medical History information was reported.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .25 milliliter. In February 2022, the patient experienced IMMUNODEFICIENCY (Diagnosed with a condition that made him immunocompromised). At the time of the report, IMMUNODEFICIENCY (Diagnosed with a condition that made him immunocompromised) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication details were reported.  No treatment medication details were reported.
Red, inflamed, tender, hot skin are with induration, marked the outer edges, almost 8cm long and 6 cm wide - going on for 7 days, looks like cellulitis --> prescribe antibiotics, hot compresses and follow up.
severe pain done her arm; arm felt heavy; nausea; not feeling good; This spontaneous report was received from a medical assistant and refers to a 57-year-old female. The patient's medical history and concurrent conditions were not reported. Concomitant therapies were not reported.  On 15-DEC-2021, the patient started therapy with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) pre-filled syringe injection, lot #U018309, expiration date: 08-JAN-2023, administered intramuscularly into the right arm for immunisation (strength was not provided).   On 17-DEC-2021, the patient experienced severe pain done her arm (pain in extremity), her arm felt heavy (limb discomfort ), nausea (nausea) and not feeling good (malaise). The patient did not seek medical attention.  No treatment was given for the events.  The outcome of aforementioned events was unknown.   The reporter did not assess the causal relationship between therapy with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) and the events.
Received vaccine on 3/16. Arm became incredibly sore/unusable for 2 days, followed by one day (3/18) of flu-like symptoms. I then started to experience occasional, mild tinnitus, which is still persisting.  On 3/22 I woke up with significant pain in my armpit that extended from my left breast through my elbow. This pain is still persisting, though less severe. On 3/26 I experienced an extreme episode of vertigo, lasting about 30 minutes, followed by an hour of vomiting. I have never had vertigo before. I continued to experience dizziness and nausea for the next 48 hours, and I'm still experiencing issues with blurred vision.  On the afternoon of 3/26, I had a televisit with a primary care physician to discuss the vertigo episode. She advised I take meclizine for the nausea and said she  could not diagnose anything conclusively unless another episode occurs.
Excess stomach acid within 5-10 minutes.  At 1 hour, upper lip swelling. I took 50mg Benadryl and the swelling went down after an hour. At 3 hours I became overly sleepy, and elbow and knees began to ache.
My symptoms began on the evening of 05/29. I first noticed fatigue and was just really tired that evening. I woke up the morning of 5/30 with a slight fever, sore throat and congestion and was feeling body aches and fatigue and my symptoms persisted through the entire day and the next day, 5/31. I took an at home Covid test on 5/30 and went to my local urgent clinic on 05/31 who advised that I just rest and isolate. On 06/01, the body aches and sore throat had subsided, but I was still feeling congestion and fatigue which lasted to 06/03 and I took another Covid test that day which was positive. The fatigue lasted through to 06/06 but it wasn't as bad. I intent to take another at home Covid test today, 06/07 to see if I'm still positive.
Client was given a dose of IPV when it was not indicated for client's age.  Client was up to date on IPV.   Client did not have a reaction to the vaccine.
Fever; Muscle aches; This is a spontaneous report from a contactable healthcare professional (patient). A 24-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EJ1686; Expiration date was not reported) on 30Dec2020 (08:45) at a single dose on the left arm, with route of administration and therapy date unspecified, for COVID-19 immunization at a public health clinic. Medical history included COVID-19 prior to vaccination. There were no concomitant medications. On 30Dec2020 (20:00), the patient had fever and muscle aches. The patient had not been tested for COVID-19 post-vaccination, and did not receive any treatment for the reported adverse events. The outcome of the events, fever and muscle aches, was recovered on 31Dec2020.
Headache Fever 100.9 Muscle aches in joints Swollen lymph nodes in the left armpit with pain
This is a literature report for the following literature source(s): "Upper Extremity Deep Venous Thrombosis after BNT162B2 mRNA COVID-19 Vaccine", Journal of General Internal Medicine, 2022. A 60-year-old female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown), in left deltoid for covid-19 immunisation. The patient's relevant medical history included: "hypertension" (unspecified if ongoing); "nephrolithiasis" (unspecified if ongoing); "Covid-19" (unspecified if ongoing), notes: 4 months prior; "no tobacco use" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1; manufacturer unknown), for COVID-19 immunisation. The following information was reported: DEEP VEIN THROMBOSIS (medically significant), 6 days after the suspect product(s) administration, outcome "unknown", described as "Upper Extremity Deep Venous Thrombosis after BNT162B2 mRNA COVID-19 Vaccine". The event "upper extremity deep venous thrombosis after bnt162b2 mRNA covid-19 vaccine" required emergency room visit. The patient underwent the following laboratory tests and procedures: Angiogram: was confirmatory; Cancer screening: unknown result; Cardiac function test: unremarkable; Coagulation test: Negative; Electrocardiogram: was notable for more pronounced t-wave inversions, notes: in III and aVF; Left bicep circumference: 31cm versus 28cm on the right; SARS-CoV-2 test: negative, notes: and denied shortness of breath, cough, fever, or dyspnea on exertion; Ultrasound scan: deep venous thrombosis (DVT), notes: deep venous thrombosis (DVT) left internal jugular, subclavian, axillary, and basilic veins; Venogram: showed persistent clot burden in the left, notes: axillary, mid-subclavian, and brachiocephalic veins. Eleven days later. Therapeutic measures were taken as a result of deep vein thrombosis. Sender's Comments: As there is limited information in the case provided, the causal association between the event deep vein thrombosis with the suspect product BNT162b2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Swelling and puffiness in the face and around the eyes red face and fever. This occurred about 27 hours after the vaccine dosage for the Moderna COVID-19 vaccine.
pt recvd vax in rt deltoid & 48-72 hrs later moderate swelling in rt interior axillary area;
Pt received the second COVID shot on 8/31/21. On 9/1/21 he developed a headache, body aches, chills, and a low grade fever. On 9/3/21 he developed dull sternal chest pain that radiated to the center of his back, neck tightness, and bilateral shoulder pain around noon. He was also pale and diaphoretic.  Mom called the PCP after these symptoms started. PCP directed mom to take pt to the ED. He was taken to Hospital Emergency Room on 9/3/21. Chest pain resoled on its own before pt arrived in the ED, according to the ED report. In the ED labs were drawn, EKG, and Chest Xray were completed.  Pt was admitted to cardiology in stable condition for an echocardiogram in observation as well as to trend his cardiac enzymes. Pt was monitored overnight via telemetry. Echocardiogram was completed on 9/4/21. Two repeat Troponin levels were drawn the morning of 9/4/21, 6 hrs apart from one another. Pt was discharged home due to a normal echocardiogram and asymptomatic status. Pt has a follow up appointment with Cardiology on 9/9/21. Cardiology will do another echo and draw another Troponin level. Cardiology recommended no athletic activity until cleared by Cardiologist.
For lot 083J21A put in the fridge on 07Feb2022, and date of administration on 12-Apr-2022; Expired doses of Moderna COVID-19 were administered beyond the beyond use date.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired doses of Moderna COVID-19 were administered beyond the beyond use date.) and PRODUCT STORAGE ERROR (For lot 083J21A put in the fridge on 07Feb2022, and date of administration on 12-Apr-2022) in a 76-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 083J21A) for COVID-19 prophylaxis.     No Medical History information was reported.  On 12-Apr-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired doses of Moderna COVID-19 were administered beyond the beyond use date.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (For lot 083J21A put in the fridge on 07Feb2022, and date of administration on 12-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired doses of Moderna COVID-19 were administered beyond the beyond use date.) and PRODUCT STORAGE ERROR (For lot 083J21A put in the fridge on 07Feb2022, and date of administration on 12-Apr-2022) outcome was unknown.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Patient took total 4 doses. Took booster 2 dose of Moderna on 12-Apr-2022. Patient received vaccine on 07-Feb-2022., Lot number 083J21A was refrigerated on 7-Feb-2022. Vial did not undergo any temperature excursion.  Treatment information was not provided.   This case was linked to MOD-2022-584673, MOD-2022-584679 (Patient Link).
This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On an unknown date, the patient was vaccinated with an improperly stored dose of PROQUAD lot # N021727, expiration date 06-FEB-2019, (dose, route and frequency were not reported) for prophylaxis; administered along with a properly stored sterile diluent, Lot # N016995, expiration date 08-OCT-2019 (dose, route and frequency were not reported). The improperly stored vaccine was noticed due to a data logger. It was stored between 15 Fahrenheit degrees (F) and 46 F (average of 37 F) during 24 hours; and there was a second excursion between 6 F and 14 F (average of 11 F) during 1 hour. There were no previous temperature excursions. No adverse effects were reported. No product quality complaint (PQC) was involved.
Information has been received from a nurse referring to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 27-APR-2016 the patient was vaccinated with an improperly stored dose of M-M-R II (rHA) (lot#I023386, expiration date 25-JUN-2017, dose and route unknown) and an improperly stored dose of VARIVAX (lot# reported as I04688, expiration date 23-NOV-2017, dose and route unknown). The temperature and time frame were at 14.9 Celsius degree for 280 hours. There was no out of range before. No adverse events were reported. Lot number I04688 is an invalid lot number for VARIVAX. This is one of several reports received from the same reporter. Additional information has been requested.
A report has been received from a Health Professional concerning a 2 month old, female patient. The patient received Nasal FLUMIST QAUDRIVALENT (Intranasal), 0.2 Millilitres, Once/Single administration. FLUMIST QUADRIVALENT (Intranasal) started on an unknown date. Product use issue was reported as FLUMIST was administered to a 2 month old by error. No adverse event was observed. The outcome of the event of FLUMIST administered to a 2 month old by error is unknown. The report was considered to be non-serious by company physician.
Hot swollen leg bump around to back of leg, fever, lethargy, can't walk.
Local erythema, edema, induration about 8cm in diameter at site. Within 24 hours of vaccine, she had a temp of 100.4, myalgias, pruritus, rash on upper chest, neck and upper back that is slightly raised, papular. 11/30/2005 no pruritus, erythema gone, mild induration.
Myalgia Narrative: EMPLOYEE REPORTS PAIN/STIFFNESS IN LEFT ARM